Matsuya R&D (7317) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Cumulative results for Q3 were characterized by lower revenue but higher earnings, with growth and improved profitability in the core Medical Healthcare Business driving overall earnings growth. Revenue declined to ¥72.7B (YoY -1.6%), while Operating Income rose significantly to ¥16.7B (same period +11.1%) and Ordinary Income to ¥17.3B (same period +11.8%). Net Income attributable to owners of the parent was ¥12.3B (same period +5.2%); the recognition of ¥1.3B in extraordinary losses constrained the rate of net income growth relative to Operating Income and Ordinary Income. The primary factor behind the decline in revenue was a decrease in orders for Safety Systems, but increased revenue in Medical Healthcare and company-wide profitability improvements offset this decline and resulted in higher earnings.

Factors Affecting Results

【Revenue】Company-wide Revenue was ¥72.7B, representing a YoY decline of -1.6%. The core Medical Healthcare Business (70.3% of revenue) secured revenue growth of 10.9% YoY to ¥51.1B, while Safety Systems (28.5% of revenue) declined substantially by 22.2% YoY to ¥20.7B, weighing on overall Revenue. Other Businesses contracted to ¥0.9B, down -24.0% YoY.

【Profit and Loss】Operating Income was ¥16.7B (YoY +11.1%), and the Operating Margin improved by 260bp to 23.0% from approximately 20.4% in the same period of the previous year. The Medical Healthcare segment’s 31.9% segment profit margin drove the company-wide margin, while Safety Systems also improved profitability, generating segment profit of ¥3.3B (same period +37.3%) despite lower revenue. Meanwhile, Other Businesses deteriorated from a profit in the previous year to a segment loss of ¥0.3B. Ordinary Income increased to ¥17.3B (same period +11.8%) after adding ¥0.9B in non-operating income, primarily ¥0.8B in foreign exchange gains. However, due to the recognition of ¥1.3B in extraordinary losses, profit before tax remained at ¥16.0B, and Net Income was ¥12.3B (same period +5.2%), representing a slower growth rate than Operating Income and Ordinary Income. Overall, the results were characterized by lower revenue but higher earnings.

Segment Analysis

Medical Healthcare generated Revenue of ¥51.1B (YoY +10.9%) and segment profit of ¥16.3B (same period +11.4%), making it the core business driving the company, with a segment profit margin of 31.9%. Safety Systems experienced a substantial revenue decline to ¥20.7B (same period -22.2%), but segment profit increased to ¥3.3B (same period +37.3%), improving its profit margin to 16.1%. Higher earnings despite lower revenue suggest a reduction in low-profitability projects or a change in the business mix. Other Businesses posted Revenue of ¥0.9B (same period -24.0%) and a segment loss of ¥0.3B, falling into the red from a profit of ¥0.3B in the previous year. The adjustment for company-wide expenses was -¥2.6B.

Key Financial Indicators

【Profitability】The Operating Margin was 23.0%, improving by approximately 260bp YoY, while the Net Profit Margin was 16.9%, improving by approximately 110bp YoY. ROE was 16.6%, decomposed into a Net Profit Margin of 16.9%, Total Asset Turnover of 0.619x, and Financial Leverage of 1.59x, with the high Net Profit Margin being the primary driver.【Cash Quality】DSO of 74 days, DIO of 108 days, and CCC of 156 days indicate prolonged working capital retention and suggest a structure in which earnings growth is not readily converted into cash.【Investment Efficiency】Total Asset Turnover was 0.619x, indicating a moderate level of asset efficiency. Intangible fixed assets accounted for approximately 10.0% of total assets, indicating limited concentration on a standalone basis.【Financial Soundness】The Equity Ratio was 63.1%, the Current Ratio was 304.2%, and the Quick Ratio was 286.2%, indicating high short-term payment capacity. Although the short-term debt ratio was somewhat high at 42.8%, cash and deposits of ¥40.3B exceeded four times short-term debt, limiting near-term liquidity risk.

Cash Flow Analysis

As actual figures for Operating CF, Investing CF, and Financing CF have not been disclosed, cash trends are analyzed based on changes in the balance sheet. Cash and deposits were ¥40.3B, a slight decrease from ¥41.4B in the same period of the previous year, while accounts receivable and notes receivable increased substantially to ¥19.7B from ¥13.0B in the previous year, and inventories also expanded from ¥4.8B. As a result, DSO of 74 days, DIO of 108 days, and CCC of 156 days indicate a prolonged working capital cycle, raising the possibility that cash generation has not kept pace with earnings growth. While long-term borrowings declined from ¥12.7B, short-term borrowings increased from ¥7.5B to ¥9.5B, indicating a partial increase in dependence on short-term funding. Total assets expanded from ¥109.1B to ¥117.5B, with the accumulation of retained earnings supporting the increase in net assets.

Earnings Quality

The growth in Ordinary Income (+11.8%) includes a contribution of ¥0.8B from foreign exchange gains, which accounted for most of the ¥0.9B in non-operating income. These foreign exchange gains were equivalent to approximately 5.0% of Operating Income and are not large enough to materially determine total earnings, but their reversal could weigh on Ordinary Income, warranting a cautious assessment of their sustainability. Profit before tax was ¥16.0B compared with Ordinary Income of ¥17.3B, with ¥1.3B in extraordinary losses—the majority of which comprised items other than losses on disposal of fixed assets—creating the difference. The fact that growth in Operating Income was supported by improved core profitability, with a stable gross margin of 33.6% and SG&A ratio of 10.6%, is positive from an earnings-quality perspective. However, the increase in accounts receivable and inventories may have expanded accruals—the divergence between earnings and cash flow—which is a point to consider when assessing the quality of Net Income.

Earnings Forecast and Guidance

Against the full-year forecast, the progress rates for Operating Income and Ordinary Income were 83.6% and 83.0%, respectively, substantially exceeding the standard progress rate of 75%. The Revenue progress rate was 75.7%, approximately in line with the standard level, while the progress rate for Net Income attributable to owners of the parent remained at 76.7%; the difference from the progress rates for Operating Income and Ordinary Income reflects the recognition of extraordinary losses. The full-year forecast calls for Revenue of ¥96.0B (YoY +0.3%), Operating Income of ¥20.0B (same period +2.4%), and Ordinary Income of ¥20.8B (same period +1.2%), and the current pace of progress indicates potential upside to core earnings.

Shareholder Returns

Both the Q2 dividend and the full-year forecast dividend are ¥0 per share, indicating that the no-dividend policy remains in place. The Payout Ratio is 0%, and as no share repurchase has been disclosed, the Total Return Ratio is effectively 0%. Profits and cash appear to be allocated to business investment, working capital, and strengthening the financial base. As Operating CF has not been disclosed, future dividend capacity cannot be assessed from a cash flow perspective.

Risk Factors

1. Prolonged working capital cycle: DSO of 74 days, DIO of 108 days, and CCC of 156 days all exceed generally cautious levels. The retention of ¥19.7B in accounts receivable and ¥4.8B in inventories is an impediment to converting earnings growth into cash.

2. Variability in profitability and growth across segments: While profit concentration in Medical Healthcare is increasing, Safety Systems’ Revenue declined substantially by -22.2% YoY, requiring an assessment of whether its earnings growth is temporary and attributable to project mix or reflects sustained efficiency improvements. Other Businesses have also shifted to a segment loss.

3. Dependence on foreign exchange gains and extraordinary losses: Foreign exchange gains of ¥0.8B contributed to the increase in Ordinary Income, making results susceptible to the impact of a reversal. In addition, ¥1.3B in extraordinary losses was recognized, constraining the growth rate of Net Income relative to Operating Income and Ordinary Income; the details and recurrence of these losses require confirmation.

Industry Benchmark (For Reference; Company Analysis)

Industry Benchmark (manufacturing)

Profitability and Returns

Both the Company’s Operating Margin and Net Profit Margin substantially exceed the industry median, placing it in the high-profitability group within the industry.

Growth and Capital Efficiency

The Revenue growth rate is below the industry median, positioning the Company as having growth-related challenges within the industry in terms of improving profitability without accompanying revenue growth.

※Source: Company analysis

Key Takeaways from the Results

1. The core Medical Healthcare Business continued to achieve higher revenue and earnings (Revenue +10.9%, profit +11.4%) and maintained high profitability, with a segment profit margin of 31.9%. This is noteworthy as a central fact underpinning the company-wide earnings structure.

2. The full-year progress rates for both Operating Income and Ordinary Income were in the 83% range, exceeding the standard 75%. While core business results are progressing at a pace above plan, the Net Income progress rate was somewhat constrained at 76.7% due to the impact of extraordinary losses.

3. The prolonged working capital cycle, reflected in DSO of 74 days, DIO of 108 days, and CCC of 156 days, indicates that a structural gap may be emerging between earnings growth and cash generation. Future trends in accounts receivable and inventory levels will be key points to monitor when assessing financial quality.

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, and you should consult a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q3 was a strong profitability quarter despite a modest top-line contraction. Revenue declined 1.6% YoY to ¥7.271bn, while operating income increased 11.1% to ¥1.671bn. Ordinary income rose 11.8% to ¥1.726bn and net income attributable to owners increased 5.2% to ¥1.230bn. The operating margin expanded to 23.0% from 20.4% in the prior-year period, a 260bp improvement. Gross margin improved to 33.6% from 30.8%, or approximately 280bp, indicating materially improved production profitability and/or sales mix. Net margin rose to 16.9% from 15.8%, an approximately 110bp expansion. The Medical Healthcare segment was the principal earnings engine, delivering ¥5.109bn of sales and ¥1.633bn of segment profit. Safety System revenue contracted sharply, but its segment margin expanded materially, supporting consolidated earnings growth. The revenue decline therefore reflects a segment-mix shift rather than broad deterioration in profit generation. The Q3 operating-income progress rate against full-year guidance reached 83.6%, exceeding the standard nine-month progress level of 75.0% by 8.6ppt. Ordinary-income progress was similarly strong at 83.0%, while revenue progress of 75.7% was broadly in line with the seasonal benchmark. Net-income progress reached 76.8%, modestly ahead of the standard level despite a ¥125m extraordinary loss. Foreign-exchange gains of ¥84m supported ordinary income, although they were not the primary driver of operating performance. Balance-sheet liquidity remains robust, with cash of ¥4.031bn, a 304.2% current ratio, and net cash of approximately ¥1.812bn after interest-bearing debt. The principal earnings-quality issue is working-capital intensity, as receivables increased 51.4% YoY and annualized DSO, DIO, and cash conversion cycle are elevated. Full-year guidance appears achievable on the reported nine-month run rate, but conversion of reported profits into cash and normalization of the working-capital cycle are central to the forward outlook.

Profitability Analysis

Annualized DuPont ROE is 22.1%, comprising a 16.9% net profit margin, 0.825x asset turnover, and 1.59x financial leverage. The dominant contributor to returns is the exceptionally high margin profile rather than aggressive balance-sheet leverage. The operating margin improved 260bp YoY to 23.0%, while gross margin increased about 280bp to 33.6%, showing that the earnings improvement originated primarily above the SG&A line. SG&A was essentially flat at ¥771m versus ¥769m in the prior-year period, despite revenue declining 1.6%; this created favorable operating leverage and supported operating-income growth of 11.1%. The modest gap between gross-margin expansion and operating-margin expansion indicates that corporate costs also rose, with unallocated corporate expenses increasing to ¥264m from ¥236m. Medical Healthcare is the core business by segment-profit contribution, generating 84.3% of total segment profit before corporate costs. Its sales increased 10.9% YoY to ¥5.109bn and segment profit increased 11.4% to ¥1.633bn, with a segment margin of 32.0% versus 31.8%. Safety System sales fell 22.2% to ¥2.071bn, but segment profit rose 37.4% to ¥333m; its segment margin improved to 16.1% from 9.1%, a roughly 700bp gain. Other sales decreased 24.0% to ¥92m and the segment recorded a ¥30m loss, versus a ¥31m profit previously. The 5-factor decomposition remains sound: the tax burden was 0.768, the interest burden was 0.958, and interest coverage was a very strong 71.6x. Annualized ROA is approximately 14.5%, using annualized nine-month net income and average total assets, reinforcing that returns are high even before the effect of leverage. The ¥125m extraordinary loss reduced the translation of ordinary income into pre-tax profit, tempering otherwise stronger bottom-line growth.

Growth Assessment

Revenue performance was mixed across the portfolio. Medical Healthcare growth of 10.9% more than offset part of the contraction in Safety System and demonstrates the strategic importance of the company’s higher-margin core business. Safety System’s revenue decline of 22.2% is the main source of consolidated sales contraction and creates a concentration risk if Medical Healthcare demand slows. Nevertheless, Safety System’s large margin recovery suggests that profitability can improve even during lower-volume periods through mix, pricing, or production-efficiency measures. Consolidated gross profit increased 7.5% YoY to ¥2.442bn despite lower revenue, which is a constructive indication of margin-led earnings resilience. Full-year revenue guidance is ¥9.600bn, implying a Q4 revenue requirement of approximately ¥2.328bn. Full-year operating-income guidance is ¥2.000bn, implying a Q4 requirement of approximately ¥329m, substantially below the average quarterly operating income earned in the first nine months. The operating-income guidance therefore appears conservative relative to the current cumulative run rate, although quarterly seasonality and project timing remain relevant. Full-year net-income guidance of ¥1.603bn requires approximately ¥373m in Q4 net income. Foreign-exchange gains were ¥84m in Q3 cumulative results, or about 5.0% of operating income, so a weaker currency tailwind would modestly reduce ordinary-income support. The construction-in-progress balance increased to ¥324m from ¥109m, indicating an ongoing investment pipeline that could support capacity or operational capability but also requires execution discipline.

Financial Health

Liquidity is strong, with current assets of ¥8.154bn against current liabilities of ¥2.681bn, resulting in a current ratio of 304.2% and working capital of ¥5.473bn. The quick ratio of 286.2% confirms that liquidity is supported predominantly by cash and receivables rather than reliance on inventory liquidation. Cash and deposits of ¥4.031bn exceed interest-bearing debt of ¥2.219bn, producing net cash of approximately ¥1.812bn. Debt-to-equity is conservative at 0.59x, debt-to-capital is 23.0%, and neither metric indicates excessive balance-sheet leverage. Interest coverage of 71.6x provides a substantial cushion against financing-cost increases. Short-term loans increased 26.7% YoY to ¥950m, and short-term debt represents 42.8% of interest-bearing debt. This refinancing-risk alert is relevant because a larger portion of borrowings must be rolled over within the year; however, the impact is moderated by cash equal to 4.24x short-term debt and by the very strong current ratio. Accounts receivable rose ¥668m YoY to ¥1.969bn, a 51.4% increase and a major balance-sheet movement relative to the 1.6% sales decline. This increase is consistent with the elevated annualized DSO of 74 days and should be monitored for collection timing and customer-credit exposure. Retained earnings increased 18.5% YoY to ¥6.520bn, underpinning equity growth to ¥7.409bn. Intangible assets represent 10.0% of total assets, a moderate level that does not indicate unusual intangible-asset concentration. Foreign-currency translation adjustments reduced comprehensive income to ¥674m, well below net income, illustrating meaningful translation sensitivity in equity.

Notable B/S Changes

Accounts receivable: +¥668m (+51.4%) to ¥1.969bn - materially outpaced revenue trends and is consistent with elevated annualized DSO of 74 days; collection timing and customer-credit quality are important. Short-term loans: +¥200m (+26.7%) to ¥950m - increased reliance on short-term funding contributes to the 42.8% short-term debt ratio, although ¥4.031bn of cash provides substantial refinancing coverage. Construction in progress: +¥215m (+196.6%) to ¥324m - signals a meaningful investment pipeline and raises the importance of project completion, timing, and return-on-investment execution. Total equity: +¥477m (+6.9%) to ¥7.409bn - retained earnings growth strengthened capital, although foreign-currency translation effects limited comprehensive income. Property, plant and equipment: +¥161m (+8.1%) to ¥2.147bn - reflects continued manufacturing-asset investment, including the increase in construction in progress.

Cash Flow Quality

Working-capital efficiency is the main cash-conversion concern. Annualized DSO is 74 days, above the 60-day warning threshold, and aligns with the substantial ¥668m YoY increase in trade receivables. Annualized DIO is 108 days, above the 90-day warning threshold, indicating that production and inventory capital are tied up for an extended period. The annualized cash conversion cycle is 156 days, exceeding the 120-day warning level and increasing the amount of operating capital required to sustain growth. Raw materials of ¥1.248bn and work in process of ¥171m indicate significant production-cycle capital deployment alongside ¥482m of finished goods. The combination of high receivable days and inventory days can delay the conversion of accounting profits into available cash, particularly if Medical Healthcare growth requires higher production and customer financing. Trade payables were ¥453m and electronically recorded obligations were ¥101m, providing some supplier financing, but not enough to offset the elevated operating-capital cycle. The increase in short-term borrowing should therefore be evaluated partly in the context of working-capital funding needs. The improvement in gross profit and operating income is favorable, but sustainable cash generation will depend on receivable collection and inventory normalization rather than further balance-sheet expansion. Construction in progress of ¥324m, up from ¥109m, also indicates cash demands associated with the investment program.

Dividend Sustainability

The company reported a ¥0 Q2 dividend per share and full-year dividend guidance is also ¥0 per share. Accordingly, the dividend payout ratio is 0% based on reported EPS of ¥57.60 and forecast EPS of ¥75.12. Retained earnings of ¥6.520bn and total equity of ¥7.409bn provide substantial internal capital relative to the current absence of cash dividends. The conservative dividend stance preserves financial flexibility while receivables, inventories, and construction in progress absorb operating and investment capital. With no indicated dividend commitment, sustainability is not constrained by current earnings or liquidity. Future capital-allocation assessment should focus on whether the company prioritizes working-capital normalization, investment spending, debt reduction, or shareholder distributions as profitability expands.

Risk Assessment

Business risks include Safety System revenue declined 22.2% YoY to ¥2.071bn, leaving consolidated growth increasingly dependent on Medical Healthcare., Medical Healthcare represents 70.3% of consolidated revenue and 84.3% of segment profit before corporate costs, creating concentration in the core earnings driver., Manufacturing operations face execution risk from extended production-cycle capital, with annualized inventory days of 108 days., Foreign-exchange exposure remains relevant: FX gains were ¥84m, equivalent to approximately 5.0% of operating income, while foreign-currency translation adjustments reduced comprehensive income by ¥557m..

Financial risks include Annualized receivable days of 74 and a 51.4% YoY receivables increase raise customer-collection and operating-capital risk., The annualized 156-day cash conversion cycle is above the 120-day warning benchmark and can increase reliance on internal cash or short-term financing., Short-term debt accounts for 42.8% of interest-bearing debt, creating refinancing exposure despite ample cash coverage., The ¥125m extraordinary loss, equal to about 10.2% of net income, reduced bottom-line conversion from ordinary income..

Key concerns include Highest priority: collection discipline and inventory turnover, because elevated DSO, DIO, and cash conversion directly affect cash availability., High priority: durability of Safety System’s margin recovery while its revenue base contracts materially., Moderate priority: the ability of Medical Healthcare growth to continue offsetting weakness in other segments without increasing concentration risk., Moderate priority: exchange-rate volatility, which affects both reported non-operating income and comprehensive income., Moderate priority: completion and return profile of the expanded construction-in-progress balance..

Investment Implications

Key takeaways include Operating profitability improved meaningfully: operating income grew 11.1% despite a 1.6% decline in revenue., Medical Healthcare is the core profit engine, with a 32.0% segment margin and 84.3% of segment profit before corporate costs., Safety System delivered substantial margin expansion to 16.1%, but its 22.2% revenue decline remains the principal operating headwind., Annualized ROE of 22.1% and annualized ROA of approximately 14.5% are strong and are driven mainly by high margins rather than elevated leverage., Liquidity and debt service capacity are robust, supported by net cash of approximately ¥1.812bn and 71.6x interest coverage., Working-capital efficiency is the key factor that could differentiate reported earnings growth from realized cash generation..

Metrics to watch include Medical Healthcare revenue growth and segment margin, Safety System revenue stabilization and maintenance of its 16.1% segment margin, Annualized DSO of 74 days and trade-receivables balance of ¥1.969bn, Annualized DIO of 108 days and raw-material, WIP, and finished-goods levels, Annualized cash conversion cycle of 156 days, Short-term loan balance of ¥950m and short-term debt ratio of 42.8%, Q4 delivery against ¥9.600bn revenue, ¥2.000bn operating-income, and ¥1.603bn net-income guidance, Foreign-exchange gains and foreign-currency translation adjustments.

Regarding relative positioning, The company exhibits above-benchmark profitability, with a 23.0% operating margin, 16.9% net margin, and 22.1% annualized ROE, alongside conservative leverage and high liquidity. Its relative financial profile is stronger than that of a typical leveraged manufacturer, but its operating-capital cycle is materially weaker than manufacturing efficiency benchmarks and is the principal counterweight to an otherwise favorable earnings profile.